RhumbLine Advisers’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$56.7M Buy
267,727
+4,380
+2% +$860K 0.04% 348
2026
Q1
$51.6M Sell
263,347
-13,116
-5% -$2.55M 0.04% 342
2025
Q4
$48M Buy
276,463
+2,017
+0.7% +$367K 0.04% 361
2025
Q3
$52.3M Sell
274,446
-5,282
-2% -$937K 0.04% 349
2025
Q2
$50.2M Sell
279,728
-7,490
-3% -$1.3M 0.04% 356
2025
Q1
$48.6M Buy
287,218
+7,578
+3% +$1.24M 0.05% 345
2024
Q4
$42.2M Sell
279,640
-8,647
-3% -$1.34M 0.04% 393
2024
Q3
$44.8M Sell
288,287
-4,903
-2% -$732K 0.04% 373
2024
Q2
$40.1M Buy
293,190
+177
+0.1% +$24.2K 0.04% 383
2024
Q1
$39M Buy
293,013
+9,968
+4% +$1.29M 0.04% 399
2023
Q4
$39M Sell
283,045
-6,764
-2% -$889K 0.04% 378
2023
Q3
$35.3M Sell
289,809
-3,426
-1% -$456K 0.04% 383
2023
Q2
$41.2M Sell
293,235
-339
-0.1% -$46.7K 0.05% 348
2023
Q1
$41.5M Sell
293,574
-12,443
-4% -$1.78M 0.05% 327
2022
Q4
$47.9M Buy
306,017
+1,999
+0.7% +$287K 0.06% 281
2022
Q3
$37.3M Buy
304,018
+2,757
+0.9% +$363K 0.06% 314
2022
Q2
$40.1M Buy
301,261
+20,987
+7% +$2.86M 0.06% 287
2022
Q1
$38.4M Buy
280,274
+2,732
+1% +$381K 0.05% 329
2021
Q4
$48M Buy
277,542
+1,926
+0.7% +$293K 0.06% 287
2021
Q3
$40M Sell
275,616
-14,819
-5% -$2.17M 0.05% 307
2021
Q2
$38.3M Buy
290,435
+168
+0.1% +$22K 0.05% 329
2021
Q1
$37.3M Buy
290,267
+2,010
+0.7% +$248K 0.05% 328
2020
Q4
$34.4M Sell
288,257
-21,407
-7% -$2.61M 0.05% 350
2020
Q3
$35.5M Sell
309,664
-35,234
-10% -$4.16M 0.06% 298
2020
Q2
$39.3M Sell
344,898
-63,618
-16% -$6.75M 0.07% 262
2020
Q1
$32.8M Buy
408,516
+40,695
+11% +$4.21M 0.07% 258
2019
Q4
$39.3M Buy
367,821
+13,437
+4% +$1.4M 0.07% 277
2019
Q3
$37.9M Buy
354,384
+9,114
+3% +$936K 0.07% 259
2019
Q2
$35.2M Buy
345,270
+44,024
+15% +$4.23M 0.07% 278
2019
Q1
$27.1M Sell
301,246
-17,160
-5% -$1.49M 0.05% 328
2018
Q4
$26.5M Sell
318,406
-4,082
-1% -$383K 0.06% 305
2018
Q3
$34.8M Buy
322,488
+11,639
+4% +$1.28M 0.07% 285
2018
Q2
$34.2M Sell
310,849
-3,251
-1% -$339K 0.07% 284
2018
Q1
$31.5M Sell
314,100
-5,728
-2% -$587K 0.07% 298
2017
Q4
$31.5M Sell
319,828
-1,175
-0.4% -$111K 0.06% 300
2017
Q3
$30.1M Buy
321,003
+13,503
+4% +$1.43M 0.07% 294
2017
Q2
$34.2M Sell
307,500
-20,049
-6% -$2.12M 0.08% 266
2017
Q1
$32.2M Sell
327,549
-8,116
-2% -$774K 0.08% 278
2016
Q4
$30.8M Buy
335,665
+57,769
+21% +$4.98M 0.08% 266
2016
Q3
$23.5M Buy
277,896
+11,040
+4% +$927K 0.06% 298
2016
Q2
$21.7M Buy
266,856
+19,921
+8% +$1.52M 0.06% 301
2016
Q1
$17.6M Buy
246,935
+44,727
+22% +$3M 0.05% 337
2015
Q4
$14.4M Sell
202,208
-889
-0.4% -$59.8K 0.05% 392
2015
Q3
$12.5M Buy
203,097
+2,303
+1% +$161K 0.04% 427
2015
Q2
$14.6M Buy
200,794
+9,839
+5% +$726K 0.05% 393
2015
Q1
$14.7M Sell
190,955
-840
-0.4% -$60.2K 0.04% 382
2014
Q4
$12.9M Sell
191,795
-1,582
-0.8% -$99.8K 0.04% 418
2014
Q3
$11.7M Sell
193,377
-5,504
-3% -$339K 0.04% 432
2014
Q2
$11.7M Sell
198,881
-13,208
-6% -$773K 0.03% 441
2014
Q1
$12.3M Sell
212,089
-7,613
-3% -$408K 0.04% 427
2013
Q4
$11.8M Sell
219,702
-24,788
-10% -$1.47M 0.03% 436
2013
Q3
$15.1M Buy
244,490
+1,715
+0.7% +$103K 0.05% 373
2013
Q2
$14.7M Buy
+242,775
New +$14.5M 0.05% 356

Other funds holding DGX

RhumbLine Advisers's DGX Position: Q2 2026 in Review

RhumbLine Advisers increased its Quest Diagnostics (DGX) stake by 1.7% in Q2 2026, buying an estimated $860K and bringing the position to 267,727 shares worth $56.7M. The position accounts for 0.04% of the portfolio, ranked #348.

RhumbLine Advisers first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • RhumbLine Advisers held 267,727 shares of Quest Diagnostics worth $56.7M as of Q2 2026.
  • RhumbLine Advisers bought 4,380 Quest Diagnostics shares in Q2 2026, an estimated $860K.
  • Quest Diagnostics made up 0.04% of RhumbLine Advisers's portfolio in Q2 2026, its #348 holding.
  • RhumbLine Advisers first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.